Alcon and RxSight Inc. have forged a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).
Under the joint effort, the companies will innovate on their respective platforms—RxSight’s post-operative light-adjustable technology and Alcon’s PCIOL optical designs—and combine them to create a co-developed technology that enables surgeons to fine-tune visual outcomes for cataract patients who choose a PCIOL.
“Our PCIOLs have helped millions of patients reduce or eliminate the need for glasses after cataract surgery,” Alcon CEO David J. Endicott said. “Together with RxSight’s technology, we have the opportunity to develop tunable PCIOLs, giving surgeons even greater confidence to refine outcomes after surgery.”
As part of the agreement, RxSight will receive a $60 million upfront payment to begin development. RxSight could receive up to an additional $140 million in payments as development and regulatory milestones are met. Under the agreement, Alcon will lead global commercialization and RxSight will oversee development and manufacturing, receiving royalties on net sales.
“We are excited to work with Alcon to provide patients greater access to outcomes customized to their needs after surgery,” RxSight CEO Ron Kurtz stated. “This collaboration underscores our belief in the importance of adjustability and will help accelerate its expansion across a wider base of patients.”
With a heritage spanning more than 75 years, Alcon offers products to enhance sight and improve lives. Its Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. The company’s more than 25,000 associates enhance the quality of life through products, partnerships with eye care professionals, and programs that advance access to quality eye care.
RxSight Inc. is an ophthalmic medical device company providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprising the RxSight Light Adjustable Lens (LAL/LAL+, collectively the “LAL”), RxSight Light Delivery Device (LDD), and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery.